Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02717624 · ClinicalTrials.gov registry record · Phase 1

A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL

A Phase 1 study of Mantle Cell Lymphoma (MCL), sponsored by Acerta Pharma.

Active
Registry status
Phase 1
Development phase
72
Enrollment target
15
Study locations

NCT02717624 is a Phase 1 study of Mantle Cell Lymphoma (MCL) that is active but no longer recruiting, run by Acerta Pharma. The registered enrollment target is 72 participants, below the 201-participant average among 9 other Mantle Cell Lymphoma (MCL) trials with a reported enrollment target (64% lower). The trial reports 15 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02717624, a Phase 1 study of Mantle Cell Lymphoma (MCL), is active but no longer recruiting, sponsored by Acerta Pharma.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
72 participants
Enrollment target
15
Study locations

Study Summary

A Phase 1b, Multicenter, Open-label Study of Acalabrutinib in Combination with Bendamustine and Rituximab (BR) or Venetoclax and Rituximab (VR) in Subjects with Mantle Cell Lymphoma

Conditions Studied

Mantle Cell Lymphoma (MCL)

Interventions

  • DRUG Acalabrutinib in combination with BR
  • DRUG Acalabrutinib in combination with VR

Study Locations (15)

Other

  • Research Site - Bologna
  • Research Site - Krakow
  • Research Site - Lodz
  • Research Site - Olsztyn
  • Research Site - Warsaw

New Jersey

  • Research Site - Hackensack
  • Research Site - Morristown

Washington

  • Research Site - Seattle
  • Research Site - Seattle

Kentucky

  • Research Site - Louisville

Michigan

  • Research Site - Ann Arbor

New York

  • Research Site - Lake Success

Ohio

  • Research Site - Columbus

Tennessee

  • Research Site - Nashville

Trial Details

FieldValue
Enrollment Target 72 participants
Start Date 2016-04-20
Est. Completion 2027-08-20
Phase Phase 1

Sponsor

Acerta Pharma

38 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02717624

The ClinicalTrials.gov registry entry for NCT02717624 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 201-participant average among 9 other Mantle Cell Lymphoma (MCL) trials with a reported enrollment target (64% lower). The listed sponsor is Acerta Pharma, which has 38 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Mantle Cell Lymphoma (MCL) appearing as the primary indexed condition, and to 2 interventions - of which Acalabrutinib in combination with BR is the first listed.

NCT02717624 reports 15 study locations spanning 9 distinct geographic areas - top geographies include Other, New Jersey, Washington.

Frequently Asked Questions

What is clinical trial NCT02717624 about?

NCT02717624 is a clinical study titled "A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL". A Phase 1b, Multicenter, Open-label Study of Acalabrutinib in Combination with Bendamustine and Rituximab (BR) or Venetoclax and Rituximab (VR) in Subjects with Mantle Cell Lymphoma

What is the current status of trial NCT02717624?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2016-04-20. Estimated completion is 2027-08-20.

What conditions does trial NCT02717624 study?

This clinical trial studies the following conditions: Mantle Cell Lymphoma (MCL).

What interventions are being tested in trial NCT02717624?

The interventions under investigation include: Acalabrutinib in combination with BR (DRUG), Acalabrutinib in combination with VR (DRUG).

Who is sponsoring clinical trial NCT02717624?

This trial is sponsored by Acerta Pharma, which has 38 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02717624 being conducted?

This trial has 15 study locations across Kentucky, Michigan, New Jersey, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Mantle Cell Lymphoma (MCL)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Mantle Cell Lymphoma (MCL)

All registered trials for this condition

Kentucky

All trials with a study site in Kentucky

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.